Search results for "Vaccination."

showing 10 items of 654 documents

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeableH…

2016

ABSTRACT Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib…

Malemedicine.medical_specialtyAntipyreticsparacetamolImmunologyIbuprofenBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causeGastroenterologyHaemophilus influenzaePneumococcal Vaccines03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineAntipyretic10-valent pneumococcal conjugateAcetaminophenfeverPharmacologyReactogenicityRomaniabusiness.industryIncidenceorganic chemicalsImmunogenicityInfantIbuprofenResearch PapersAntibodies BacterialHealthy VolunteersAcetaminophenVaccinationTreatment OutcomeImmunologyFemaleprophylaxisbusinessmedicine.drugHuman Vaccines & Immunotherapeutics
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly.

2017

Background Through its effects on the immune system, smoking may facilitate influenza virus infection, its severity and its most frequent complications. The objective was to investigate the smoking history as a risk factor for influenza hospitalization and influenza vaccine effectiveness in elderly smokers/ex-smokers and non-smokers. Methods We carried out a multicenter case-control study in the 2013-2014 and 2014-2015 influenza seasons. Cases aged ≥65 years and age-, sex-matched controls were selected from 20 Spanish hospitals. We collected epidemiological variables, comorbidities, vaccination history and the smoking history. The risk of hospitalization due to smoking (current smokers and …

Malemedicine.medical_specialtyInfluenza vaccineComorbidity03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologyInfluenza HumanMedicineHumans030212 general & internal medicineRisk factorGeriatric AssessmentAgedAged 80 and overbusiness.industrySmokingPublic Health Environmental and Occupational HealthCase-control studyOdds ratiomedicine.diseaseComorbidityVaccinationHospitalizationIncreased riskTreatment Outcome030228 respiratory systemInfluenza VaccinesSpainCase-Control StudiesFemaleMedical emergencybusinessEuropean journal of public health
researchProduct

Influenza Vaccination After Myocardial Infarction:A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

2021

Background: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Methods: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.3%). The primary end point was the composite of all-cause death, MI, or stent thrombosis at 12 months. A hierarchical testing strategy was used for the key secondary end points: all-cause death, cardiovascular death, MI, and stent thrombosis. Results: Because of the COV…

Malemedicine.medical_specialtyInfluenza vaccineMEDLINEMyocardial Infarction030204 cardiovascular system & hematologyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawPhysiology (medical)Multicenter trialInternal medicineinfluenza vaccinesmedicineHumans030212 general & internal medicineMyocardial infarctionbusiness.industryMiddle Agedmedicine.disease3. Good healthVaccinationTreatment Outcomemyocardial infarctionInfluenza Vaccinesrandomized controlled trialObservational studyFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

2010

Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the over…

Malemedicine.medical_specialtyMeasles-Mumps-Rubella VaccineInfluenza vaccineAntibodies ViralVaccines AttenuatedRubellaMeaslesDrug IncompatibilityPlacebosRubella vaccineInternal medicineInfluenza HumanmedicineLive attenuated influenza vaccineHumansVaccines CombinedMumpsAdministration IntranasalRubellaGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessMeasles-Mumps-Rubella Vaccinemedicine.drugMeaslesVaccine
researchProduct

UNIVERSAL VARICELLA VACCINATION IN THE SICILIAN PAEDIATRIC POPULATION: RAPID UPTAKE OF THE VACCINATION PROGRAMME AND MORBIDITY TRENDS OVER FIVE YEARS

2009

Following the licensure of the Oka/Merck varicella vaccine in Italy in January 2003, the Sicilian health authorities launched a universal vaccination programme in all nine Local Health Units. A two-cohort vaccination strategy was adopted to minimise the shift of the mean age of varicella occurrence to older age groups, with the goal of vaccinating with one dose at least 80% of children in their second year of life and 50% of susceptible adolescents in their 12th year of life. Two studies were implemented in parallel to closely monitor vaccination coverage as well as varicella incidence. Overall, the programme achieved its target, with 87.5% vaccine coverage for the birth cohort 2005 and 90.…

Malemedicine.medical_specialtyPediatricsHerpesvirus 3 HumanVaricella vaccineSettore MED/17 - Malattie InfettiveAdolescentEpidemiologyVaricella vaccinationPediatricsChickenpox VaccineChickenpoxVirologymedicineHumansChildSicilybusiness.industryImmunization ProgramsIncidence (epidemiology)Public healthIncidencePublic Health Environmental and Occupational HealthInfantConfidence intervalVaccinationEl NiñoImmunizationChild PreschoolPopulation SurveillanceFemaleViral diseaseMorbiditybusiness
researchProduct

Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors.

2005

Abstract Objective To investigate frequency and associated factors of post polio syndrome (PPS) in an Italian cohort of people with prior poliomyelitis. Methods We screened subjects admitted for poliomyelitis at the paediatric hospital of the University of Palermo during the time frame 1945–1960. Patients who developed PPS were identified through a structured questionnaire and a neurologic examination. PPS diagnosis was made according to specified diagnostic criteria. Frequency of PPS was calculated in the selected cohort of polio survivors. The association with the investigated risk factors (sex, age at onset of polio, extension and severity of polio, education, associated diseases, cigare…

Malemedicine.medical_specialtyPediatricseducationPrevalenceCohort StudiesPost-polio syndromeRisk FactorsSurveys and QuestionnairesmedicinePrevalenceHumansRisk factorhealth care economics and organizationsNeurologic ExaminationChi-Square Distributionbusiness.industryOdds ratioMiddle Agedmedicine.diseasePolio VaccinationPoliomyelitisSurgeryPoliomyelitiNeurologyCohortPost-polio syndromeSettore MED/26 - NeurologiaFemaleRisk factorNeurology (clinical)Postpoliomyelitis SyndromeCohort studybusinessCohort studyPoliomyelitisJournal of the neurological sciences
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

2015

Background: To evaluate the immunological situation against hepatitis B virus (HBV) of a cohort of dentistry students, to analyze the behavior of the levels of hepatitis B surface antigen (anti-HBs) after the administration of one or three vaccine doses, and to determine the influence of age and sex on the immune response. Material and Methods: This retrospective cohort study included students attending the School of Dentistry of the institution where the study was performed from 2005 to 2012 who had completed the public health vaccination calendar for HBV at the age of 12-13. Data on age, sex, basal anti-HBs levels, post-vaccination anti-HBs results and final anti-HBs levels were collected…

Malemedicine.medical_specialtyUniversitieseducationStudents DentalOdontologíamedicine.disease_causeCohort StudiesYoung AdultInternal medicinemedicineHumansHepatitis B VaccinesYoung adultGeneral DentistryRetrospective StudiesHepatitis B virusOral Medicine and PathologyHepatitis B Surface Antigensbiologybusiness.industryResearchRetrospective cohort studyHepatitis B:CIENCIAS MÉDICAS [UNESCO]Hepatitis Bmedicine.diseaseCiencias de la saludVaccinationOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASImmunologyCohortbiology.proteinFemaleSurgeryAntibodybusinessCohort studyMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Oral HPV Infection: Current Strategies for Prevention and Therapy

2012

Infection with High Risk (HR) Human Papillomaviruses (HPVs) is the main aetiological agent of Cervical Squamous Cell Carcinoma (CSCC) and also associated in a subgroup of other neoplasms, including Oropharyngeal Squamous cell Carcinoma (OPSCC). HPV infection, in genital as in oral mucosa, can also be subclinical or associated with benign proliferative lesions (common warts, condylomas, papillomas) caused mostly by infection with Low Risk (LR)-HPVs. In the last decades, extensive research has resulted in growing knowledge on HPV biology and specifically viral life cycle, biochemical properties of viral proteins and their interaction with the host proteins leading to potential new targets of …

Malemedicine.medical_specialtyUterine Cervical NeoplasmsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryEpidemiologyAnimalsHumansMedicineSex organPapillomavirus VaccinesHealth EducationCommon wartsSubclinical infectionPharmacologyta313business.industryTransmission (medicine)Papillomavirus InfectionsHPV infectionvirus diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationOropharyngeal NeoplasmsCervical Squamous Cell CarcinomaHigh Risk (HR)HPV infectionDNA ViralImmunologyCarcinoma Squamous CellEtiologyRNA ViralFemaleMouth DiseasesbusinessCurrent Pharmaceutical Design
researchProduct